Press "Enter" to skip to content

Biotechnology Company Introduces The Value Chain For Stakeholders

Orion Biotechnology Canada Ltd. today introduced that Dr. Thomas Hecht has been appointed Chairman of its Board of Directors. Dr. Hecht brings intensive experience in leading value creation processes for stakeholders across the full value chain as well as deal-making with large pharmaceutical and biotechnology companies. In the new position, he will also use his expertise as Chairman of a variety of energetic and former Boards; he, at the moment, serves as Chairman of the board at Affimed N.V. Aelix Therapeutics S.L. and Vaximm AG and as a member of the Board of Administrators of Cellmedica Ltd. Dr. Hecht held numerous positions at Amgen between 1989 and 2002, including Head of Medical Affairs and Vice President Advertising at Amgen Europe. He’s additionally head of Hecht Healthcare Consulting in Switzerland, the biopharmaceutical consulting company.

Orion Biotechnology is honored to this exceptional chief as Chair of our Board of Administrators,” stated Mark Groper, President and CEO, Orion Biotechnology. Thomas’s lengthy and distinguished profession, having a long time of leadership in the growth and delivery of new medicines, makes him uniquely certified to guide our Board at this pivotal moment in Orion’s growth. We’re delighted that a biotech executive of such worldwide stature will be leading our Board of Administrators.”

Orion Biotechnology wishes to prolong sincere because of Rudolf Bom for his position as founding Chair. Mr. Bom will stay as a Director on the Board in addition to Vice-Chair and can proceed to offer the experience and sound guidance that has been instrumental within the Firm’s success so far.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *